2018 Section 6 - Laryngology, Voice Disorders, and Bronchoesophalogy

S. E. Attwood et al.

REFERENCES 1. Moayyedi P, Leontiadis GI. The risks of PPI therapy. Nat Rev Gastroenterol Hepatol 2012; 9 : 132 – 9. 2. Reimer C. Safety of long-term PPI therapy. Best Pract Res Clin Gastroenterol 2013; 27 : 443 – 54. 3. Ali T, Roberts DN, Tierney WM. Long- term safety concerns with proton pump inhibitors. Am J Med 2009; 122 : 896 – 903. 4. Agewall S, Cattaneo M, Collet JP, et al. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. Eur Heart J 2013; 34 : 1708 – 13. 5. Chen J, Yuan YC, Leontiadis GI, Howden CW. Recent safety concerns with proton pump inhibitors. J Clin Gastroenterol 2012; 46 : 93 – 114. 6. Fiocca R, Mastracci L, Attwood SE, et al. Gastric exocrine and endocrine cell morphology under prolonged acid inhibition therapy: results of a 5-year follow-up in the LOTUS trial. Aliment Pharmacol Ther 2012; 36 : 959 – 71. 7. Fiocca R, Mastracci L, Engstrom C, et al. Long-term outcome of microscopic esophagitis in chronic GERD patients treated with esomeprazole or laparoscopic antire fl ux 8. Lundell L, Miettinen P, Myrvold HE, et al. Comparison of outcomes twelve years after antire fl ux surgery or omeprazole maintenance therapy for re fl ux esophagitis. Clin Gastroenterol Hepatol 2009; 7 : 1292 – 8. 9. Lundell L, Attwood S, Ell C, et al. Comparing laparoscopic antire fl ux surgery with esomeprazole in the management of patients with chronic gastro-oesophageal re fl ux disease: a 3- year interim analysis of the LOTUS trial. Gut 2008; 57 : 1207 – 13. 10. Galmiche JP, Hatlebakk J, Attwood S, et al. Laparoscopic antire fl ux surgery vs esomeprazole treatment for chronic GERD: the LOTUS randomized clinical trial. JAMA 2011; 305 : 1969 – 77. 11. Freston JW, Hisada M, Peura DA, et al. The clinical safety of long-term lansoprazole for the maintenance of healed erosive oesophagitis. Aliment Pharmacol Ther 2009; 29 : 1249 – 60. 12. Katz PO, Castell DO, Chen Y, Andersson T, Sostek MB. Intragastric acid suppression and pharmacokinetics surgery in the LOTUS trial. Am J Gastroenterol 2010; 105 : 1015 – 23.

H 2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 2006; 79 : 76 – 83. 23. Targownik LE, Lix LM, Leung S, Leslie WD. Proton pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 2010; 138 : 896 – 904. 24. Kaye JA, Jick H. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy 2008; 28 : 951 – 9. 25. Garcia Rodriguez L, Cea Soriano L, Ruigomez A, Johansson S. A UK primary care study on acid-suppressive drugs and hip fracture: is there a link? Gut 2011; 60 (Suppl. 3): A36. 26. Garcia Rodriguez LA, Ruigomez A, Panes J. Use of acid-suppressing drugs and the risk of bacterial gastroenteritis. Clin Gastroenterol Hepatol 2007; 5 : 1418 – 23. 27. Neal KR, Scott HM, Slack RC, Logan RF. Omeprazole as a risk factor for campylobacter gastroenteritis: case- control study. BMJ 1996; 312 : 414 – 5. 28. Cunningham R, Dale B, Undy B, Gaunt N. Proton pump inhibitors as a risk factor for Clostridium dif fi cile diarrhoea. J Hosp Infect 2003; 54 : 243 – 5. 29. Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk of community-acquired 30. Gulmez SE, Holm A, Frederiksen H, Jensen TG, Pedersen C, Hallas J. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med 2007; 167 : 950 – 5. 31. Sarkar M, Hennessy S, Yang YX. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med 2008; 149 : 391 – 8. 32. Dublin S, Walker RL, Jackson ML, Nelson JC, Weiss NS, Jackson LA. Use of proton pump inhibitors and H2 blockers and risk of pneumonia in older adults: a population-based case- control study. Pharmacoepidemiol Drug Saf 2010; 19 : 792 – 802. 33. Estborn L, Joelson S. Frequency and time to onset of respiratory tract infections in esomeprazole and placebo treated patients pneumonia and use of gastric acid- suppressive drugs. JAMA 2004; 292 : 1955 – 60.

of twice-daily esomeprazole: a randomized, three-way crossover study. Aliment Pharmacol Ther 2004; 20 : 399 – 406. 13. FDA. FDA ’ s Safety Reviews of Prilosec and Nexium Find No Evidence of Increased Rates of Cardiac Events. Available at: http://www.fda.gov/ NewsEvents/Newsroom/Press Announcements/2007/ucm109037.htm and http://www.fda.gov/Drugs/Drug Safety/PostmarketDrugSafety InformationforPatientsandProviders/ ucm143258.htm 2007 (accessed 16 September 2014). 14. Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010; 363 : 1909 – 17. 15. O ’ Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical ef fi cacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009; 374 : 989 – 97. 16. Mattsson H, Havu N, Brautigam J, Carlsson K, Lundell L, Carlsson E. Partial gastric corpectomy results in hypergastrinemia and development of gastric enterochromaf fi nlike-cell carcinoids in the rat. Gastroenterology 1991; 100 : 311 – 9. 17. Jianu CS, Fossmark R, Viset T, et al. Gastric carcinoids after long-term use of a proton pump inhibitor. Aliment Pharmacol Ther 2012; 36 : 644 – 9. 18. Ito T, Jensen RT. Association of long- term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium. Curr Gastroenterol Rep 2010; 12 : 448 – 57. 19. Marcuard SP, Albernaz L, Khazanie PG. Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin B12). Ann Intern Med 1994; 120 : 211 – 5. 20. Valuck RJ, Ruscin JM. A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 de fi ciency in older adults. J Clin Epidemiol 2004; 57 : 422 – 8. 21. Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006; 296 : 2947 – 53. 22. Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine

in 24 randomized controlled trials (UEGW 2013 poster P1617) 2013.

Aliment Pharmacol Ther 2015; 41: 1162 – 1174 ª 2015 John Wiley & Sons Ltd

187